SIRPA and cancer: Although the aforementioned anti-SIRPα antibodies have not entered the clinical trial stage, some anti-SIRPα antibodies have demonstrated good biosafety and cancer treatment efficacy in preclinical studies and have thus entered clinical trials (Table 2).